The Pros and Cons of Corporate VCs

There are both advantages and disadvantages for financial VCs considering a co-investment by a corporate venture investor. The pros include, the ability to draw on the extensive due diligence resources of the corporate parent company; benefiting from the corporate VC's skills at evaluating later stage risk; and the corporate VC's perspective of the customer. On the downside, the unpredictability of corporate VCs' ability to make follow-on investments; different expectations on returns; and potential conflicts-of-interest. In general, though corporate VC investment is a very good thing, and any associated negatives can be handled through the structuring of the relationship and by making sure that there are consistent expectations on both sides.

Question: How do institutional venture capitalists regard the proposed investment by a corporate venture fund in a later (Series B or after) financing round of a biotech or medical device company?

Answer: Corporate venture funds have different missions and thus employ different investment practices. That makes it difficult to generalize institutional venture funds' reaction to the introduction of a corporate player...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By 

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By 

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

 
• By 

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By 

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.

More from Business

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By 

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.

Roivant Staying ‘Patient’ On Deals, Leaving Investors Waiting

 

CEO Matt Gline talked to Scrip in an interview about dealmaking and the road back to commercialization.